Published in J Virol on November 06, 2013
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers | NCT01381744
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 9.00
The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature (2011) 6.21
The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol (2013) 4.75
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
The CD8+ dendritic cell subset. Immunol Rev (2010) 3.32
Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol (2012) 3.18
Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol (2010) 2.68
The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies. Virology (1982) 1.94
Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol (2001) 1.92
Modulation of inflammasome pathways by bacterial and viral pathogens. J Immunol (2011) 1.85
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis (2011) 1.82
Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol (2011) 1.80
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology (2005) 1.74
Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol (2001) 1.70
Effects of flagellin on innate and adaptive immunity. Immunol Res (2005) 1.58
Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine (2011) 1.51
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol (2006) 1.42
A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol (2010) 1.33
Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol (2005) 1.28
Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol (2004) 1.28
The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection. J Virol (2011) 1.27
Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol (2007) 1.24
Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol (2009) 1.20
Distribution of M protein and nucleocapsid protein of vesicular stomatitis virus in infected cell plasma membranes. Virus Res (1989) 1.19
Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection. Curr Opin Microbiol (2013) 1.19
Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol (2010) 1.14
Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol (2006) 1.14
Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol (2008) 1.13
A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol (2010) 1.11
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol (2011) 1.05
Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol (2010) 1.04
Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol (2006) 0.98
Inflammasome activation via intracellular NLRs triggered by bacterial infection. Cell Microbiol (2011) 0.93
Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine (2011) 0.93
Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations. PLoS One (2013) 0.93
Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J Virol (2008) 0.88
Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol (2010) 0.81
Immunogenicity of repeated Sendai viral vector vaccination in macaques. Microbes Infect (2012) 0.76
Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J Virol (2002) 1.78
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology (2004) 1.53
Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol (2005) 1.28
Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev (2011) 1.22
Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol (2003) 1.22
Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology (2007) 1.22
ApoA-I structure on discs and spheres. Variable helix registry and conformational states. J Biol Chem (2002) 1.20
Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol (2006) 1.18
Inhibition of host and viral translation during vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral but not host translation. J Biol Chem (2005) 1.15
Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol (2006) 1.14
Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol (2008) 1.13
The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol (2003) 1.12
Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol (2004) 1.10
Organization of the vesicular stomatitis virus glycoprotein into membrane microdomains occurs independently of intracellular viral components. J Virol (2003) 1.09
Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms. J Virol (2009) 1.07
Role of residues 121 to 124 of vesicular stomatitis virus matrix protein in virus assembly and virus-host interaction. J Virol (2006) 1.07
Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol (2007) 1.06
Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol (2008) 1.05
hnRNPs Relocalize to the cytoplasm following infection with vesicular stomatitis virus. J Virol (2008) 1.04
Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol (2010) 1.04
Plasma membrane microdomains containing vesicular stomatitis virus M protein are separate from microdomains containing G protein and nucleocapsids. J Virol (2008) 1.01
Vesicular stomatitis virus induces apoptosis primarily through Bak rather than Bax by inactivating Mcl-1 and Bcl-XL. J Virol (2009) 0.99
Functional, cognitive and psychological outcomes, and recurrent vascular events in Pakistani stroke survivors: a cross sectional study. BMC Res Notes (2012) 0.98
Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. J Vasc Interv Neurol (2012) 0.97
Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neural cells by vesicular stomatitis virus. Virology (2002) 0.96
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95
Ligand binding promotes the entropy-driven oligomerization of integrin alpha IIb beta 3. J Biol Chem (2002) 0.94
Complexes of vesicular stomatitis virus matrix protein with host Rae1 and Nup98 involved in inhibition of host transcription. PLoS Pathog (2012) 0.92
Interferon response and viral evasion by members of the family rhabdoviridae. Viruses (2009) 0.92
Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery (2012) 0.89
Myeloid cell-specific ABCA1 deletion protects mice from bacterial infection. Circ Res (2012) 0.88
Vesicular stomatitis virus matrix protein mutations that affect association with host membranes and viral nucleocapsids. J Biol Chem (2008) 0.86
The roles of IL-12 and IL-23 in CD8+ T cell-mediated immunity against Listeria monocytogenes: Insights from a DC vaccination model. Cell Immunol (2010) 0.86
New mRNAs are preferentially translated during vesicular stomatitis virus infection. J Virol (2007) 0.85
Analgesic activity of various extracts of Holoptelea integrifolia (Roxb.) Planch leaves. Pak J Pharm Sci (2012) 0.84
The disintegrin echistatin stabilizes integrin alphaIIbbeta3's open conformation and promotes its oligomerization. J Mol Biol (2004) 0.84
Assembly of arenavirus envelope glycoprotein GPC in detergent-soluble membrane microdomains. J Virol (2009) 0.83
Antineoplastic activity of Holoptelea integrifolia (Roxb.) Planch bark extracts (in vitro). Pak J Pharm Sci (2013) 0.82
Pseudotypes of vesicular stomatitis virus with CD4 formed by clustering of membrane microdomains during budding. J Virol (2005) 0.82
Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. J Virol (2012) 0.82
Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol (2010) 0.81
Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. PLoS One (2013) 0.79
Treatment options for atypical optic neuritis. Indian J Ophthalmol (2014) 0.78
Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery (2013) 0.76
Left atrial volumes and associated stroke subtypes. BMC Neurol (2013) 0.75
Atomic absorption spectroscopic analysis of some Pakistani herbal medicinal products used in respiratory tract infections. Pak J Pharm Sci (2012) 0.75